Coagulation factors and inhibitors in thawed plasma stored at 1-6°C for 5days in China

Transfusion and Apheresis Science

Volumn 50, Issue 2, 2014, Pages 274-280

  Wang, Zongkui ^a   Du, Xi ^a   Li, Changqing ^a   Ma, Li ^a   Sun, Pan ^a   Cao, Haijun ^a   Lin, Fangzhao ^a   Ye, Shengliang ^a   Xiao, Xiaopu ^a  

^a INSTITUTE OF BLOOD TRANSFUSION   (China)

Author keywords

Coagulation factors; Coagulation inhibitors; Plasma storage; Thawed plasma

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; FIBRINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

APHERESIS; ARTICLE; BLOOD CLOTTING TEST; CHINA; HUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PROTHROMBIN TIME; STORAGE TEMPERATURE; THAWING; THROMBIN TIME; CHEMISTRY; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; MALE; PROTEIN STABILITY; RANDOMIZED CONTROLLED TRIAL; TIME;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CRYOPRESERVATION; FEMALE; HUMANS; MALE; PARTIAL THROMBOPLASTIN TIME; PLASMA; PROTEIN STABILITY; TIME FACTORS;

EID: 84900505769     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2014.01.002     Document Type: Article

References (41)

1. Roback J.D., Caldwell S., Carson J., Davenport R., Drew M.J., Eder A., et al. Evidence-based practice guidelines for plasma transfusion. Transfusion 2010, 50:1227-1239.
2. Kozek-Langenecker S., Sorensen B., Hess J.R., Spahn D.R. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care 2011, 15:R239.
3. Yang L., Stanworth S., Hopewell S., Doree C., Murphy M. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials (CME). Transfusion 2012, 52:1673-1686.
4. AABB. The circular of information for blood and blood products: Bethesda, MD: AABB; 2009.
5. O'shaughnessy D., Atterbury C., Bolton Maggs P., Murphy M., Thomas D., Yates S., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Brit J Haematol 2004, 126:11-28.
6. The technical specifications of clinical blood transfusion 2012, Ministry of Health, Beijing.
7. Gosselin R.C., Marshall C., Dwyre D.M., Gresens C., Davis D., Scherer L., et al. Coagulation profile of liquid-state plasma. Transfusion 2013, 53:579-590.
8. FDA. FDA approves Octaplas to treat patients with blood clotting disorders. U.S. Food and Drug Administration. 2013 [cited 13.08.13]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336009.htm.
9. Sheffield W.P., Bhakta V., Mastronardi C., Ramirez-Arcos S., Howe D., Jenkins C. Changes in coagulation factor activity and content of di(2-ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing. Transfusion 2012, 52:493-502.
10. Huisman E.L., van Eerd M.C., Ouwens J., de Peuter M.A. Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (OctaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada. Transfus Apher Sci 2013, (May 28). Epub ahead of print.
11. Bux J., Dickhorner D., Scheel E. Quality of freeze-dried (lyophilized) quarantined single-donor plasma. Transfusion 2013, 53:3203-3209.
12. Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011, 100:169-178.
13. Lamboo M., Poland D.C., Eikenboom J.C., Harvey M.S., Groot E., Brand A., et al. Coagulation parameters of thawed fresh-frozen plasma during storage at different temperatures. Transfus Med 2007, 17:182-186.
14. Tholpady A., Monson J., Radovancevic R., Klein K., Bracey A. Analysis of prolonged storage on coagulation factor (F)V, FVII, and FVIII in thawed plasma: is it time to extend the expiration date beyond 5 days?. Transfusion 2013, 53:645-650.
15. Theusinger O.M., Baulig W., Seifert B., Emmert M.Y., Spahn D.R., Asmis L.M. Relative concentrations of haemostatic factors and cytokines in solvent/detergent-treated and fresh-frozen plasma. Brit J Anaesth 2011, 106:505-511.
16. Theusinger O.M., Baulig W., Asmis L.M., Seifert B., Spahn D.R. In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM®). Thromb Haemostasis 2010, 104:385-391.
17. Kohler H.P. Interaction between FXIII and fibrinogen. Blood 2013, 121:1931-1932.
18. Sidhu R.S., Le T., Brimhall B., Thompson H. Study of coagulation factor activities in apheresed thawed fresh frozen plasma at 1-6°C for 5days. J Clin Apheresis 2006, 21:224-226.
19. Scott E., Puca K., Heraly J., Gottschall J., Friedman K. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-h plasma at thaw and after 120h of 1-6°C storage. Transfusion 2009, 49:1584-1591.
20. Bhakta V., Jenkins C., Ramirez-Arcos S., Sheffield W.P. Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5days post-thaw. Transfusion 2013, (May 21). [Epub ahead of print].
21. Matijevic N., Kostousov V., Wang Y.-W.W., Wade C.E., Wang W., Letourneau P., et al. Multiple levels of degradation diminish hemostatic potential of thawed plasma. J Trauma 2011, 70:71-80.
22. Downes K.A., Wilson E., Yomtovian R., Sarode R. Serial measurement of clotting factors in thawed plasma stored for 5days. Transfusion 2001, 41:570.
23. Aggeler P.M. Physiological basis for transfusion therapy in hemorrhagic disorders: a critical review. Transfusion 1961, 1:71-86.
24. Murray D.J., Olson J., Strauss R., Tinker J.H. Coagulation changes during packed red cell replacement of major blood loss. Anesthesiology 1988, 69:839-845.
25. Franchini M., Favaloro E., Lippi G. Mild hemophilia A. J Thromb Haemost 2010, 8:421-432.
26. Alhumaidan H., Cheves T., Holme S., Sweeney J. Stability of coagulation factors in plasma prepared after a 24-h room temperature hold. Transfusion 2010, 50:1934-1942.
27. AABB. Statement before BPAC on production of plasma products - 3/17/05 statement of AABB before the blood products advisory committee: American Association of Blood Banks. 2005 [cited 13.08.13]. http://www.aabb.org/pressroom/statements/Pages/bpacplasma031705.aspx.
28. Spector I., Corn M., Ticktin H.E. Effect of plasma transfusions on the prothrombin time and clotting factors in liver disease. New Engl J Med 1966, 275:1032-1037.
29. Keller M.K., Pruss A., Sander M., Spies C., Schoenfeld H., Schuster M., et al. Thawed solvent/detergent-treated plasma: too precious to be wasted after 6h?. Blood Transfus 2012, 10:360-367.
30. Keller M.K., Krebs M., Spies C., Wernecke K.D., Heger A., von Heymann C. Clotting factor activity in thawed Octaplas® LG during storage at 2-6°C for 6 days from a quality assurance point of view. Transfus Apher Sci 2012, 46:129-136.
31. Buchta C., Felfernig M., Höcker P., Macher M., Körmöczi G., Quehenberger P., et al. Stability of coagulation factors in thawed, solvent/detergent-treated plasma during storage at 4°C for 6days. Vox Sang 2004, 87:182-186.
32. Scott E.A., Puca K.E., Pietz B.C., DuChateau B.K., Friedman K.D. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion 2007, 47:120-125.
33. Heger A., Kannicht C., Romisch J., Svae T.E. Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development. Vox Sang 2007, 92:206-212.
34. Flamholz R., Jeon H.R., Baron J.M., Baron B.W. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses?. J Clin Apheresis 2000, 15:169-172.
35. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004, 11:346-350.
36. Yarranton H., Lawrie A., Purdy G., Mackie I., Machin S. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004, 14:39-44.
37. Kauvar D.S., Lefering R., Wade C.E. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma 2006, 60:S3-S11.
38. Zink K.A., Sambasivan C.N., Holcomb J.B., Chisholm G., Schreiber M.A. A high ratio of plasma and platelets to packed red blood cells in the first 6h of massive transfusion improves outcomes in a large multicenter study. Am J Surg 2009, 197:565-570.
39. Radwan Z.A., Bai Y., Matijevic N., del Junco D.J., McCarthy J.J., Wade C.E., et al. An emergency department thawed plasma protocol for severely injured patients. JAMA Surg 2013, 148:170-175.
40. Mitra B., Mori A., Cameron P.A., Fitzgerald M., Paul E., Street A. Fresh frozen plasma (FFP) use during massive blood transfusion in trauma resuscitation. Injury 2010, 41:35-39.
41. Snyder C.W., Weinberg J.A., McGwin G., Melton S.M., George R.L., Reiff D.A., et al. The relationship of blood product ratio to mortality: survival benefit or survival bias?. J Trauma 2009, 66:358-364.